Great Ormond Street Hospital, London, United Kingdom.
Early Hum Dev. 2011 Oct;87(10):683-90. doi: 10.1016/j.earlhumdev.2011.05.009. Epub 2011 Jun 22.
Retinopathy of prematurity (ROP) is a potentially blinding disease of premature infants and despite timely treatment some infants develop retinal detachment and sight loss. Current treatment utilises laser therapy which causes destruction of treated retinal tissue resulting in field loss. There is considerable research work ongoing on neovascular eye disease which is likely to result in antiangiogenic approaches that will arrest the development of ROP by specifically targeting the involved molecular mediators. Some of these new therapeutic interventions have entered clinical trials. This article reviews new information available on the molecular pathogenesis of ROP which may result in novel treatments for ROP; it does not discuss the well-known role of oxygen in the development of ROP.
早产儿视网膜病变（ROP）是一种潜在致盲性疾病，尽管及时治疗，一些婴儿仍会出现视网膜脱离和视力丧失。目前的治疗方法是激光治疗，会导致治疗后的视网膜组织破坏，从而导致视野丧失。目前正在进行大量关于新生血管性眼病的研究，这些研究很可能会采用抗血管生成的方法，通过特异性靶向相关的分子介质来阻止 ROP 的发展。其中一些新的治疗方法已经进入临床试验。本文综述了 ROP 分子发病机制方面的新信息，这些信息可能为 ROP 提供新的治疗方法；本文不讨论氧在 ROP 发展中的已知作用。
